Where Do We Stand in the Management of Oligometastatic Prostate Cancer? A Comprehensive Review
Juan Gómez Rivas, Fernández Hernández Laura, Puente Vázquez Javier, Vidal Casinello Natalia, Galante Romo Ma Isabel, Redondo González Enrique, Senovilla Pérez José Luis, Abad López Pablo, Sanmamed Salgado Noelia, Vives Dilme Roser, Jesús Moreno Sierra
Abstract
Oligometastatic prostate cancer (OMPC) is an intermediate state between localised disease and widespread metastases that includes a spectrum of disease biology and clinical behaviours. This narrative review will cover the current OMPC scenario. We conducted comprehensive English language literature research for original and review articles using the Medline database and grey literature through December 2021. OMPC is a unique clinical state with inherently more indolent tumour biology susceptible to multidisciplinary treatment (MDT). With the development of new imaging techniques, patients with OMPC are likely to be identified at an earlier stage, and the paradigm for treatment is shifting towards a more aggressive approach to treating potentially curable patients. Multimodal management is necessary to improve patient outcomes due to the combination of available therapies, such as local therapy of primary tumour, metastasis directed therapy or systemic therapy, to reduce tumour load and prevent further disease progression. Additional prospective data are needed to select patients most likely to benefit from a given therapeutic approach.